NASDAQ:PDEX Pro-Dex (PDEX) Stock Price, News & Analysis → Are You Positioned For The New Energy Goldrush? (From Wealthpin Pro) (Ad) Free PDEX Stock Alerts $19.71 +0.11 (+0.56%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$19.58▼$20.0550-Day Range$17.22▼$20.2252-Week Range$14.51▼$22.99Volume3,639 shsAverage Volume9,229 shsMarket Capitalization$67.41 millionP/E Ratio33.98Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Pro-Dex alerts: Email Address Ad Weiss RatingsOn June 10, Nvidia makes its next big moveA small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. We call them Nvidia’s “Silent Partners.”Click here to find out who they are. About Pro-Dex Stock (NASDAQ:PDEX)Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.Read More PDEX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PDEX Stock News HeadlinesMay 28, 2024 | americanbankingnews.comPro-Dex (NASDAQ:PDEX) Downgraded by StockNews.com to BuyMay 21, 2024 | finance.yahoo.comPro-Dex, Inc. (PDEX)May 3, 2024 | investorplace.comPDEX Stock Earnings: Pro-Dex Misses EPS, Beats Revenue for Q3 2024April 26, 2024 | msn.comHow to use Samsung Dex for gamingApril 23, 2024 | msn.comWhat is Samsung DeX and how does it work?April 19, 2024 | money.usnews.comPro-Dex Inc. (co)April 9, 2024 | msn.comAutoPro X accessory will bring Samsung DeX to your vehicleApril 2, 2024 | benzinga.comVicarious Surgical Stock (NYSE:RBOT), Quotes and News SummaryMarch 15, 2024 | seekingalpha.comMonogram Orthopaedics reports FY resultsFebruary 22, 2024 | finance.yahoo.comThe Returns On Capital At Pro-Dex (NASDAQ:PDEX) Don't Inspire ConfidenceFebruary 8, 2024 | finance.yahoo.comPro-Dex, Inc. Announces Fiscal 2024 Second Quarter and Six-Month ResultsJanuary 26, 2024 | finance.yahoo.comPro-Dex (NASDAQ:PDEX) shareholders have earned a 7.2% CAGR over the last five yearsDecember 30, 2023 | finance.yahoo.comIs Pro-Dex, Inc.'s (NASDAQ:PDEX) Latest Stock Performance A Reflection Of Its Financial Health?November 14, 2023 | finance.yahoo.comHere’s Why You Should Consider Buying Pro-Dex (PDEX) SharesNovember 10, 2023 | morningstar.comPro-Dex Inc PDEXNovember 2, 2023 | finance.yahoo.comPro-Dex, Inc. Announces Fiscal 2024 First Quarter ResultsNovember 2, 2023 | finance.yahoo.comPro-Dex Inc (PDEX) Reports 8% Increase in Q1 Fiscal 2024 Net Sales, Despite Net Loss of $615,000October 26, 2023 | finanznachrichten.deStock Day Media: Pro-Dex, Inc. Discusses 4th Quarter and Year-End Results with The Stock Day PodcastOctober 26, 2023 | finance.yahoo.comPro-Dex, Inc. Discusses 4th Quarter and Year-End Results with The Stock Day PodcastOctober 15, 2023 | finance.yahoo.comPro-Dex Inc (PDEX) Reports Fiscal 2023 Fourth Quarter and Full-Year ResultsOctober 13, 2023 | finance.yahoo.comPro-Dex, Inc. Announces Fiscal 2023 Fourth Quarter and Full-Year ResultsOctober 4, 2023 | morningstar.comNorth American Morning Briefing: S&P 500 Futures -2-August 7, 2023 | finance.yahoo.comPro-Dex's (NASDAQ:PDEX) Returns Have Hit A WallJune 29, 2023 | finance.yahoo.comAt US$18.26, Is It Time To Put Pro-Dex, Inc. (NASDAQ:PDEX) On Your Watch List?June 5, 2023 | finanznachrichten.deStock Day Media: Pro-Dex, Inc. Discusses Record 3rd Quarter Results with The Stock Day PodcastSee More Headlines Receive PDEX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pro-Dex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today6/01/2024Fiscal Year End6/30/2024Next Earnings (Estimated)10/11/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:PDEX CUSIPN/A CIK788920 Webwww.pro-dex.com Phone(949) 769-3200Fax949-769-3281Employees145Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.58 Trailing P/E Ratio33.98 Forward P/E RatioN/A P/E GrowthN/ANet Income$7.07 million Net Margins4.13% Pretax Margin5.50% Return on Equity6.50% Return on Assets4.01% Debt Debt-to-Equity Ratio0.25 Current Ratio3.45 Quick Ratio2.08 Sales & Book Value Annual Sales$46.09 million Price / Sales1.46 Cash Flow$2.29 per share Price / Cash Flow8.59 Book Value$9.05 per share Price / Book2.18Miscellaneous Outstanding Shares3,420,000Free Float1,963,000Market Cap$67.41 million OptionableNot Optionable Beta0.55 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Richard Lee Van Kirk Jr. (Age 63)CEO, President, COO & Director Comp: $418.61kMs. Alisha K. Charlton (Age 54)CFO & Corporate Secretary Comp: $297.61kKey CompetitorsT2 BiosystemsNASDAQ:TTOOLyra TherapeuticsNASDAQ:LYRAPAVmedNASDAQ:PAVMAngioDynamicsNASDAQ:ANGOOrchestra BioMedNASDAQ:OBIOView All CompetitorsInstitutional OwnershipPerritt Capital Management Inc.Bought 1,813 shares on 5/15/2024Ownership: 0.175%LSV Asset ManagementSold 3,099 shares on 5/6/2024Ownership: 0.666%View All Institutional Transactions PDEX Stock Analysis - Frequently Asked Questions How have PDEX shares performed in 2024? Pro-Dex's stock was trading at $17.52 on January 1st, 2024. Since then, PDEX stock has increased by 12.5% and is now trading at $19.71. View the best growth stocks for 2024 here. Are investors shorting Pro-Dex? Pro-Dex saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 8,800 shares, a drop of 47.0% from the April 30th total of 16,600 shares. Based on an average trading volume of 7,300 shares, the days-to-cover ratio is currently 1.2 days. Approximately 0.4% of the shares of the company are short sold. View Pro-Dex's Short Interest. When is Pro-Dex's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, October 11th 2024. View our PDEX earnings forecast. How were Pro-Dex's earnings last quarter? Pro-Dex, Inc. (NASDAQ:PDEX) issued its earnings results on Thursday, May, 2nd. The medical instruments supplier reported $0.19 earnings per share (EPS) for the quarter. The medical instruments supplier earned $14.29 million during the quarter. Pro-Dex had a trailing twelve-month return on equity of 6.50% and a net margin of 4.13%. What is Michael J. Berthelot's approval rating as Pro-Dex's CEO? 3 employees have rated Pro-Dex Chief Executive Officer Michael J. Berthelot on Glassdoor.com. Michael J. Berthelot has an approval rating of 85% among the company's employees. What other stocks do shareholders of Pro-Dex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pro-Dex investors own include KEMET (KEM), NVIDIA (NVDA), Enterprise Products Partners (EPD), Micron Technology (MU), AT&T (T), AbbVie (ABBV), Alibaba Group (BABA), Bank of America (BAC), Marvell Technology (MRVL) and UnitedHealth Group (UNH). Who are Pro-Dex's major shareholders? Pro-Dex's stock is owned by a number of institutional and retail investors. Top institutional investors include LSV Asset Management (0.67%) and Perritt Capital Management Inc. (0.18%). Insiders that own company stock include Katrina Marie Kramer Philp and William James Farrell III. View institutional ownership trends. How do I buy shares of Pro-Dex? Shares of PDEX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PDEX) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pro-Dex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
